logo
Share SHARE
FONT-SIZE Plus   Neg

Lilly Posts Trial Data On Postmenopausal Women With Back Pain - Quick Facts

Eli Lilly and Co. (LLY) reported data from a Phase III trial comparing the effects of FORTEO and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures. The study demonstrated no difference between FORTEO and risedronate on the primary endpoint of at least a 30 percent reduction in worst back pain from baseline to six months of therapy, as assessed by a numeric rating scale in each treatment group.

However, there were statistically significant differences in favor of FORTEO in some exploratory measures, including greater increases in bone mineral density and fewer patients with new vertebral fractures. The trial results are published in the August issue of Osteoporosis International.

The overall safety profile of the study was consistent with the known FORTEO safety profile seen in this patient population, as well as the overall incidence of serious adverse events, treatment-emergent adverse events and adverse events resulting in discontinuation were similar between the FORTEO and risedronate treatment groups. There were nine deaths in the study, four in the FORTEO group and five in the risedronate group, but none of the deaths were considered related to treatment, the company said.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
French conglomerate Bouygues SA reported Thursday a net loss for the first half compared to a profit last year, which was boosted by a gain on Cofiroute unit stake sale. However, sales edged up 1 percent from last year. The company raised its 2015 outlook for Bouygues Telecom and confirmed its forecast for the construction businesses and TF1 television business. Kraft Heinz is recalling more than two million pounds of Oscar Mayer turkey bacon as it may prematurely spoil and on reports of people becoming unwell after eating certain items. Apparel maker PVH Corp. said Wednesday after the markets closed that its second quarter profit fell 19% from last year, hurt mainly by a stronger U.S. dollar. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. As a result, the company once again raised its full year outlook.
comments powered by Disqus
Follow RTT